|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||88.50 - 89.51|
|52-week range||83.55 - 114.80|
|Beta (5Y monthly)||0.36|
|PE ratio (TTM)||16.48|
|Forward dividend & yield||3.52 (4.17%)|
|Ex-dividend date||06 May 2022|
|1y target est||N/A|
Sanofi provides update on amcenestrant clinical development program PARIS, August 17, 2022. Sanofi is discontinuing the global clinical development program of amcenestrant, an investigational oral selective estrogen receptor degrader (SERD). The decision is based on the outcome of a prespecified interim analysis of the Phase 3 AMEERA-5 trial evaluating amcenestrant in combination with palbociclib compared with letrozole in combination with palbociclib in patients with estrogen receptor-positive
Yahoo Finance health care reporter Anjalee Khemlani looks at which pharmaceutical stocks are being affected by litigation surrounding alleged carcinogenic materials in Zantac derivatives.
Big pharma stocks, such as Glaxo (GSK), Sanofi (SNY), Pfizer (PFE) and Consumer stock Haleon (HLN), decline due to the litigation surrounding the heartburn drug Zantac (ranitidine).